Scanning the Market's Corners: Who's Faking It and Who's Making It

I’ve been watching a grab bag of overlooked equities sitting in the market's unclassified corners lately. This is a mess—ranging from deepwater drillers to medical devices, and micro-caps struggling to stay above the minimum bid line. This is stupid and here's why: most of these companies are asleep at the wheel, using financial engineering to mask failing operations, while only a select few are actually making real money.

Let’s start with the adults in the room. Talos Energy (TALO.US) is quietly printing cash in the Gulf of Mexico. In August 2026, Mexican billionaire Carlos Slim’s family office dumped USD 150M into their bonds to fund deepwater expansions. When billionaires write checks like that, pay attention. They just posted a massive 56.5% year-over-year revenue spike in Q2 2026. Latin American financial giant XP (XP.US) is showing similar resilience. Despite a challenging macro backdrop, they grew Q2 revenue by 8% and hit a record BRL 2.2T in client assets. They clearly know what they are doing.

Then we have the AI hype riders. Backblaze (BLZE.US) calls itself a cloud platform for the AI era and did post an 18% revenue jump in Q2. But they just issued over USD 200M in convertible notes this month—a massive debt load that dilutes focus. Good luck with that. Over in road intelligence, Rekor Systems (REKR.US) bumped Q2 revenue to USD 12.7M, but they've been dodging Nasdaq delisting warnings. Management promises adjusted profitability in the second half? We'll see.

The rest of the pack is baffling. Wabash National (WBTN.US) saw Q2 trailer sales drop 9.1% and had to tap the convertible note market. Meanwhile, the Sprott Physical Gold and Silver Trust (CEF.US) somehow managed to log a net loss of over USD 933M in the first half of 2026 due to metal price fluctuations. Seriously? And TOP Financial Group (TOP.US) is playing the 1-for-5 reverse split game just to avoid getting kicked off the exchange, posting a meager USD 1.08M in Q1 revenue. Why aren't you moving faster to fix the core business instead of shuffling deck chairs?

Finally, we have the danger zone. Autonomix Medical (AMIX.US) lost USD 2.7M in Q2 and needs another USD 25M to USD 30M just to commercialize its first product. If they don't raise it, they hit a wall by Q1 2027. As for Incannex Health (IXHL.US) and Onward Holdings (ONDG.US), there’s absolute radio silence in 2026. If you can't make news in this market, you probably shouldn't be in a portfolio.

This article does not constitute investment advice.